EN DE
Watch Maze Therapeutics, Inc. Common Stock for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Maze Therapeutics, Inc. (MAZE) fair value: what the stock is really worth

As of Nov 11, 2026: fair value (intrinsic value) of Maze Therapeutics, Inc. stock $21.55, price $36.73, that is 41.3% below the price, quality 25 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US5787841007

MT Maze Therapeutics, Inc. logo Thin data Nov 11, 2026

Maze Therapeutics, Inc.

MAZE · US
Very expensive, weak quality

Our calculation puts a fair price 41% below what the stock costs today.

Positive coverage
Insiders sold $11.8M (6M)
Fair value $21.55 · Strongly overvalued
Quality 25/100
Weak Growth
Negative free cash flow
Trails peers (1/6)
Narrow moat 9/100
Thin data
Estimate
Watch Maze Therapeutics, Inc. Common Stock for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$51.84 $7.57 Fair Value $21.55 Jan 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

21‑month range $7.57 – $51.84 · fair‑value band $16.17 – $26.94 · the $36.73 price screens above the $21.55 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 11, 2026.

Follow Maze Therapeutics, Inc. Common Stock in your weekly email

Every Wednesday you see whether Maze Therapeutics, Inc. Common Stock is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States.

Show moreShow less

Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease.

The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease.

It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018.

The company was incorporated in 2017 and is based in South San Francisco, California.

Stock analysis

Maze Therapeutics, Inc. (MAZE) currently trades at $36.73, while our estimate is $21.55, 41% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $16.17 (bear) to $26.94 (bull), the price of $36.73 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Maze Therapeutics, Inc. Common Stock reported revenue of $0 in FY2025 versus $0 in FY2022. Reported net income was −$131M in FY2025.

Key figures

Market cap $2.2B Mid · P/S ratio 97.0 · EPS (TTM) $−2.48 · Return on equity −37.4% · Return on assets (EBIT) −56.0% (4-year average) · Operating margin −728% · Revenue (TTM) $20.0M · Free cash flow −$113M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 29% below its 52-week high and 64% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −41%, MAZE screens richer than that median.

Fair Value

Bear $16.17 Fair Value $21.55 Bull $26.94
Price $36.73 · Downside -41.3%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 25/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 0
Are margins and returns getting better?
Cashflow 24
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 63
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 52
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 4 officers or directors sold shares worth $11.8M and none bought.

  • SaleJason Coloma VChief Executive Officer, Director10× since May 15, 2026: 264,146 shares, avg. $27.37$7.2MNov 2, 2026
  • SaleAtul DandekarCSBO12× since Dec 29, 2025: 153,934 shares, avg. $35.44$5.5MOct 29, 2026
  • SaleHarold BernsteinPresident, R&D & CMO15× since Dec 29, 2025: 262,886 shares, avg. $35.97$9.5MOct 1, 2026
  • SalePhillips CourtneyGC and Corp. Secretary3,993 shares at $26.24$104,766Sep 3, 2026
  • SaleAmy BachrodtSVP, Finance6× since Dec 29, 2025: 37,500 shares, avg. $41.58$1.6MApr 1, 202610b5-1 plan
  • SaleCatherine A. SohnDirector29,413 shares at $39.07$1.1MJan 7, 2026

Plus 15 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

MAZE screens overvalued: fair value 41% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Earlier news

News mood ⓘNews mood, the average tone of recent news (58 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.

Compare Maze Therapeutics, Inc. Common Stock with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks

Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 25 · Bottom 25%
Fair Value upside −41.3% · Below median
Profitability
Return on assets −33.0% · Below median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 6.10× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $959.41 $1,275 +33% vs MAZE
Vertex Pharmaceuticals Incorporated VRTX $547.03 $602.68 +10% vs MAZE
Samsung Biologics Co 207940 1,430,000 KRW 1,573,000 KRW +10% vs MAZE
Genmab A/S GMAB kr 3,561 kr 3,880 +9% vs MAZE
argenx SE ARGX $977.58 $908.40 −7% vs MAZE
CSL Limited CSL A$204.54 A$181.40 −11% vs MAZE
Moderna, Inc MRNA $248.69 $158.70 −36% vs MAZE
BeOne Medicines AG 6160 HK$251.80 HK$152.80 −39% vs MAZE
Celltrion, Inc 068270 207,000 KRW 74,945 KRW −64% vs MAZE
Royalty Pharma plc RPRX $70.01 $19.01 −73% vs MAZE

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Maze Therapeutics, Inc. Common Stock: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Maze Therapeutics, Inc. Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/MAZE

Frequently asked questions

Is Maze Therapeutics, Inc. (MAZE) overvalued or undervalued?
As of Nov 11, 2026, our estimate of fair value is $21.55 versus a price of $36.73, about 41% lower (overvalued).
What is the fair value of MAZE?
Our estimate for Maze Therapeutics, Inc. is $21.55 (as of Nov 11, 2026), built from audited fundamentals. The current price: $36.73.
What is the quality score of MAZE?
Maze Therapeutics, Inc. has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Maze Therapeutics, Inc. (MAZE)?
Our calculated price target is the estimate of $21.55 (as of Nov 11, 2026). Cautious scenario $16.17, optimistic scenario $26.94. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Maze Therapeutics, Inc. Common Stock stock forecast for 2026?
Our estimate puts fair value at $21.55, about 41% lower versus a price of $36.73 (overvalued). Cautious scenario $16.17, optimistic scenario $26.94. The calculation is refreshed regularly with new filings.
What is the revenue of Maze Therapeutics, Inc. (MAZE)?
Maze Therapeutics, Inc. reported trailing-twelve-month revenue of about $20.0M (latest available figure, as of Nov 11, 2026).
What is the intrinsic value of Maze Therapeutics, Inc. (MAZE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Maze Therapeutics, Inc. it is $21.55 per share (as of Nov 11, 2026), against a price of $36.73.
Is Maze Therapeutics, Inc. Common Stock stock overvalued or undervalued in 2026?
As of Nov 11, 2026, MAZE trades above its calculated fair value: price $36.73, fair value $21.55, a gap of about −41% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MAZE?
No. The price is what the market pays today ($36.73); the fair value is what the company's own numbers justify ($21.55). For Maze Therapeutics, Inc. the two are $15.18 per share apart. That gap is exactly why we show both numbers side by side.
How much is Maze Therapeutics, Inc. Common Stock worth?
The market values Maze Therapeutics, Inc. at about $2.2B (market capitalisation, as of Nov 11, 2026). Per share that is $36.73; our models calculate a fair value of $21.55 per share.
What do the bullish and bearish scenarios say about MAZE?
Our models span a range for Maze Therapeutics, Inc.: cautious scenario $16.17, base $21.55, optimistic $26.94 per share (as of Nov 11, 2026, price $36.73). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Maze Therapeutics, Inc. (MAZE)?
Balance-sheet figures for Maze Therapeutics, Inc. (as of Nov 11, 2026): return on equity −37.4%. They feed the Quality Score of 25/100, which measures business quality independently of the share price.
How far is MAZE from its 52-week high?
Maze Therapeutics, Inc. trades at $36.73, about 29% below its 52-week high of $51.84 and 64% above the low of $22.39 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of $21.55 is for.
Which stocks are comparable to Maze Therapeutics, Inc. Common Stock?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Maze Therapeutics, Inc. Common Stock stock attractive at the current price?
The data as of Nov 11, 2026: price $36.73, calculated fair value $21.55 (−41%), Quality Score 25/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0% above its aggregate fair value. Maze Therapeutics, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Maze Therapeutics, Inc. (MAZE)?
The closing price on Nov 11, 2026 was $36.73. Our estimate is $21.55, about 41% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Maze Therapeutics, Inc. Common Stock right now?
The price sits above even our optimistic bull case ($26.94). The favourable scenario is already priced in. Weak quality (25/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Maze Therapeutics, Inc.

How large is the market capitalisation of Maze Therapeutics, Inc. (MAZE)?
The market capitalisation of Maze Therapeutics, Inc. is $2.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Maze Therapeutics, Inc. (MAZE)?
The price-to-sales ratio of Maze Therapeutics, Inc. is 97.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Maze Therapeutics, Inc. (MAZE)?
Earnings per share at Maze Therapeutics, Inc. are $−2.48. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Maze Therapeutics, Inc. (MAZE)?
The return on equity (ROE) of Maze Therapeutics, Inc. is −37.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Maze Therapeutics, Inc. (MAZE)?
On an EBIT basis the return on assets of Maze Therapeutics, Inc. is −56.0% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Maze Therapeutics, Inc. (MAZE)?
The operating margin of Maze Therapeutics, Inc. is −728% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Maze Therapeutics, Inc. (MAZE) generate?
The free cash flow of Maze Therapeutics, Inc. is −$113M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Maze Therapeutics, Inc. (MAZE) hold?
Maze Therapeutics, Inc. holds more cash than debt, $166M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Maze Therapeutics, Inc. Common Stock in the live analysis

One click puts Maze Therapeutics, Inc. Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.